Logo image of AARD

AARDVARK THERAPEUTICS INC (AARD) Stock Fundamental Analysis

NASDAQ:AARD - US0029421007 - Common Stock

8.99 USD
-0.54 (-5.67%)
Last: 8/27/2025, 5:20:00 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to AARD. AARD was compared to 193 industry peers in the Pharmaceuticals industry. AARD has a great financial health rating, but its profitability evaluates not so good. AARD does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AARD has reported negative net income.
AARD Yearly Net Income VS EBIT VS OCF VS FCFAARD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

AARD's Return On Assets of -19.04% is fine compared to the rest of the industry. AARD outperforms 61.14% of its industry peers.
AARD has a better Return On Equity (-19.84%) than 69.43% of its industry peers.
Industry RankSector Rank
ROA -19.04%
ROE -19.84%
ROIC N/A
ROA(3y)-58.64%
ROA(5y)N/A
ROE(3y)-64.21%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AARD Yearly ROA, ROE, ROICAARD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AARD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AARD Yearly Profit, Operating, Gross MarginsAARD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

9

2. Health

2.1 Basic Checks

Compared to 1 year ago, AARD has about the same amount of shares outstanding.
AARD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AARD Yearly Shares OutstandingAARD Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 5M 10M 15M 20M
AARD Yearly Total Debt VS Total AssetsAARD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 20M 40M 60M

2.2 Solvency

An Altman-Z score of 19.42 indicates that AARD is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 19.42, AARD belongs to the top of the industry, outperforming 93.26% of the companies in the same industry.
AARD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 19.42
ROIC/WACCN/A
WACCN/A
AARD Yearly LT Debt VS Equity VS FCFAARD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

AARD has a Current Ratio of 25.86. This indicates that AARD is financially healthy and has no problem in meeting its short term obligations.
AARD's Current ratio of 25.86 is amongst the best of the industry. AARD outperforms 96.37% of its industry peers.
AARD has a Quick Ratio of 25.86. This indicates that AARD is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 25.86, AARD belongs to the best of the industry, outperforming 96.37% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 25.86
Quick Ratio 25.86
AARD Yearly Current Assets VS Current LiabilitesAARD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 20M 40M 60M

More info and screens

0

3. Growth

3.1 Past

AARD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -185.61%.
EPS 1Y (TTM)-185.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

AARD is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -46.59% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-201.14%
EPS Next 2Y-70.84%
EPS Next 3Y-46.59%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AARD Yearly Revenue VS EstimatesAARD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 5M 10M 15M
AARD Yearly EPS VS EstimatesAARD Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AARD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AARD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AARD Price Earnings VS Forward Price EarningsAARD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AARD Per share dataAARD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

A cheap valuation may be justified as AARD's earnings are expected to decrease with -46.59% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-70.84%
EPS Next 3Y-46.59%

More info and screens

0

5. Dividend

5.1 Amount

AARD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AARDVARK THERAPEUTICS INC

NASDAQ:AARD (8/27/2025, 5:20:00 PM)

8.99

-0.54 (-5.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-13 2025-08-13/amc
Earnings (Next)N/A N/A
Inst Owners49.58%
Inst Owner Change2.81%
Ins Owners14.3%
Ins Owner Change0%
Market Cap195.08M
Analysts83.64
Price Target33.46 (272.19%)
Short Float %3.35%
Short Ratio10.23
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.61%
PT rev (3m)4.13%
EPS NQ rev (1m)0%
EPS NQ rev (3m)13.88%
EPS NY rev (1m)-3.84%
EPS NY rev (3m)-10.17%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.29
P/tB 1.29
EV/EBITDA N/A
EPS(TTM)-1.67
EYN/A
EPS(NY)-2.81
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS6.94
TBVpS6.94
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -19.04%
ROE -19.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-58.64%
ROA(5y)N/A
ROE(3y)-64.21%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 25.86
Quick Ratio 25.86
Altman-Z 19.42
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-185.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-201.14%
EPS Next 2Y-70.84%
EPS Next 3Y-46.59%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-207.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-126.63%
EBIT Next 3Y-64.19%
EBIT Next 5YN/A
FCF growth 1Y-212.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-210.56%
OCF growth 3YN/A
OCF growth 5YN/A